Biomea Fusion (BMEA) vs Citius Oncology (CTOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biomea Fusion (BMEA) has outperformed Citius Oncology (CTOR) over the past year, losing 18.5% versus a loss of 54.6%. Biomea Fusion is the larger company by market cap ($103.4 million vs $89.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | CTOR |
|---|---|---|
| Share price | $1.43 | $0.8497 |
| Market cap | $103.39M | $89.86M |
| 1-day change | +4.38% | +1.76% |
| YTD return | +10.48% | -16.50% |
| 1-year return | -18.45% | -54.62% |
| 5-year return | -88.22% | — |
| EPS (TTM) | $-0.29 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.24 | $2.25 |
| 52-week low | $0.872 | $0.491 |
| Distance from 52-week high | -36.08% | -62.24% |
| Analyst consensus | buy | none |
| Avg. price target upside | +389.51% | +370.75% |
| Average volume | 1.49M | 100.32K |
| Shares outstanding | 72.30M | 105.76M |
| Employees | 37 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMEA has outperformed CTOR by 36.2 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
BMEA vs CTOR FAQ
Which is bigger, Biomea Fusion or Citius Oncology?
Biomea Fusion (BMEA) is larger, with a market capitalization of $103.39M compared with $89.86M for Citius Oncology (CTOR).
Which stock has performed better over the past year, BMEA or CTOR?
BMEA returned -18.45% over the past 12 months, compared with -54.62% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Citius Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.